Treatment of Chronic Hepatitis C Using Newly Developed Oral Antiviral Agents

摘要: Standard care for chronic hepatitis C has been a combination of pegylated interferon-alpha and ribavirin, although this treatment suboptimal antiviral efficacy significant adverse events. The virus landscape transformed recently by the development direct-acting agents (DAAs) that target NS3 protease, NS5A protein, NS5B polymerase. Several DAAs showed potent activity leading to increased rates sustained virological response (SVR), even in difficult- to-treat patients such as older those with advanced liver disease prior failed peg-interferon/ribavirin treatment. Use multiple without interferon shown dramatically high SVR (up nearly 100%) negligible side effects. Interferon-free regimens are close becoming new standard USA Europe. Similarly, several near clinical use Korea. This review discusses have approved or under investigation approval (Korean J Med 2015;88:635-642)